For research use only
| Cat No. | ABC-SC2044 |
| Product Type | Human iPSCs |
| Cell Type | Induced Pluripotent Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Spinal Muscular Atrophy, TYPE II |
| Storage | Liquid Nitrogen |
Cell Type: iPSC; Disease: Spinal Muscular Atrophy, TYPE II; SMA2.
HighQC™ Human IPSC From Fibroblast-Spinal Muscular Atrophy, TYPE II
is a disease-specific induced pluripotent stem cell line derived from dermal fibroblasts of a donor diagnosed with Spinal Muscular Atrophy (SMA) Type II, an autosomal recessive disorder caused by mutations in the SMN1 gene. These cells exhibit adherent growth and maintain the capacity for trilineage differentiation into ectoderm, mesoderm, and endoderm derivatives under appropriate conditions. These iPSCs (induced pluripotent stem cells) express the core pluripotency marker SSEA-4. They preserve SMA-related physiology and enable motor neuron function study. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | HighQC™ Human IPSC From Fibroblast-Spinal Muscular Atrophy Type II, HighQC™ hiPSC SMA2, hiPSC-SMAII, HighQC™ Human Induced Pluripotent Stem Cells From Fibroblast-Spinal Muscular Atrophy Type II |
| Species | Human |
| Cat.No | ABC-SC2044 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Spinal Muscular Atrophy, TYPE II |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
| Gene Info | Gene: SMN1; Mutation: EX7-8DEL |
HighQC™ Human IPSC From Fibroblast-Spinal Muscular Atrophy, TYPE II provides a patient-specific model for in vitro developmental and disease studies. Its pluripotent capacity enables directed differentiation into motor neurons, the primary cell type affected in SMA, allowing for investigation into SMN1 gene-related pathology, motor neuron development, and disease mechanisms. This system is valuable for constructing neural organoid models to study motor circuit dysfunction and for screening potential therapeutic compounds targeting neuroprotection or SMN protein restoration.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).